Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 3/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.41 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27574336 | 0.87 | SLC1A3 (0.37) | SLC1A3SLC1A2SLC1A1ENPEPCHRM1 | |
| SCHEMBL7939626 | 0.85 | SLC1A3 (0.35) | SLC1A3SLC1A2SLC1A1CHRM1AKR1A1 | |
| SCHEMBL28237219 | 0.85 | CHRM1 (0.48) | SLC1A3SLC1A2SLC1A1CHRM1AKR1A1 | |
| SCHEMBL21269807 | 0.83 | CHRM1 (0.46) | SLC1A3SLC1A2SLC1A1CHRM1AKR1A1 | |
| SCHEMBL21269286 | 0.83 | CHRM1 (0.46) | SLC1A3SLC1A2SLC1A1CHRM1AKR1A1 | |
| Magnesium SCHEMBL29456134 | 0.83 | CHRM1 (0.46) | SLC1A3SLC1A2SLC1A1CHRM1AKR1A1 | |
| SCHEMBL28875694 | 0.83 | CHRM1 (0.46) | SLC1A3SLC1A2SLC1A1CHRM1AKR1A1 | |
| SCHEMBL21269030 | 0.83 | CHRM1 (0.46) | SLC1A3SLC1A2SLC1A1CHRM1AKR1A1 | |
| SCHEMBL28314469 | 0.83 | CHRM1 (0.46) | SLC1A3SLC1A2SLC1A1CHRM1AKR1A1 | |
| SCHEMBL28315557 | 0.83 | CHRM1 (0.46) | SLC1A3SLC1A2SLC1A1CHRM1AKR1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102007116-B | Pyridazinone glucokinase activators | HOFFMAN-LA ROCHE LTD. (CH) | 2014-10-22 | — | — | CN | disclosed |
| US-8258134-B2 | Pyridazinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | disclosed |
| CN-102007116-A | Pyridazinone glucokinase activators | HOFFMANN LA ROCHE | 2011-04-06 | — | — | CN | disclosed |
| EP-2268633-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| WO-2009127544-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-22 | — | — | WO | disclosed |
| US-7060818-B2 | Synthesis of macrocyclic tetraamido compounds and new metal insertion process | CARNEGIE MELLON UNIVERSITY (US) | 2006-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | GCK, GCKR, PDXK | SLC1A3 2766/4885SLC1A2 1961/4885SLC1A1 2613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.